Clostridium difficile infection: Same incidence and worse prognosis?

Clinical Infectious Diseases

Volumn 48, Issue 5, 2009, Pages 577-579

  Bouza, Emilio ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

METRONIDAZOLE; PROBIOTIC AGENT; VANCOMYCIN;

CANADA; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; DISEASE SEVERITY; EPIDEMIC; HUMAN; INCIDENCE; LENGTH OF STAY; MORTALITY; NONHUMAN; NOTE; PRIORITY JOURNAL; PROGNOSIS; CROSS INFECTION; DIARRHEA; ISOLATION AND PURIFICATION; MICROBIOLOGY;

CLOSTRIDIUM DIFFICILE; CROSS INFECTION; DIARRHEA; HUMANS; INCIDENCE; PROGNOSIS;

EID: 60549088961     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/596704     Document Type: Note

References (34)

1. Gravel D, Miller M, Simor A, et al. Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian Nosocomial Infection Surveillance Program study. Clin Infect Dis 2009; 48:568-76 (in this issue).
2. Zilberberg MD, Shorr AF, KollefMH. Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000-2005. Emerg Infect Dis 2008; 14:929-31.
3. Lim PL, Barkham TM, Ling LM, Dimatatac F, Alfred T, Ang B. Increasing incidence of Clostridium difficile-associated disease, Singapore. Emerg Infect Dis 2008; 14:1487-9.
4. Song X, Bartlett JG, Speck K, Naegeli A, Carroll K, Perl TM. Rising economic impact of Clostridium difficile-associated disease in adult hospitalized patient population. Infect Control Hosp Epidemiol 2008; 29:823-8.
5. Sanchez-Somolinos M, Alcala L, Pelaez T, et al. High levels of resistance to fluoroquinolones among Clostridium difficile isolates in a Spanish hospital. Clin Infect Dis 2008; 47:818-22.
6. Soler P, Nogareda F, Cano R. Rates of Clostridium difficile infection in patients discharged from Spanish hospitals, 1997-2005. Infect Control Hosp Epidemiol 2008; 29:887-9.
7. Paltansing S, van den Berg RJ, Guseinova RA, Visser CE, van der Vorm ER, Kuijper EJ. Characteristics and incidence of Clostridium difficile-associated disease in The Netherlands, 2005. Clin Microbiol Infect 2007; 13:1058-64.
8. Mooney H. Annual incidence of MRSA falls in England, but C. difficile continues to rise. BMJ 2007; 335:958.
9. Barreto AR, Cavalcante IC, Castro MV, et al. Fucoidin prevents Clostridium difficile toxin-A-induced ileal enteritis in mice. Dig Dis Sci 2008; 53:990-6.
10. Price MF, Dao-Tran T, Garey KW, et al. Epidemiology and incidence of Clostridium difficile-associated diarrhoea diagnosed upon admission to a university hospital. J Hosp Infect 2007; 65:42-6.
11. Pepin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 2005; 173:1037-42.
12. Redelings MD, Sorvillo F, Mascola L. Increase in Clostridium difficile-related mortality rates, United States, 1999-2004. Emerg Infect Dis 2007; 13:1417-9.
13. Bishara J, Peled N, Pitlik S, Samra Z. Mortality of patients with antibiotic-associated diarrhoea: the impact of Clostridium difficile. J Hosp Infect 2008; 68:308-14.
14. Zerey M, Paton BL, Lincourt AE, Gersin KS, Kercher KW, Heniford BT. The burden of Clostridium difficile in surgical patients in the United States. Surg Infect (Larchmt) 2007; 8:557-66.
15. O'Brien JA, Lahue BJ, Caro JJ, Davidson DM. The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol 2007; 28:1219-27.
16. Bouza E, Pelaez T, Alonso R, Catalan P, Munoz P, Creixems MR. "Second-look" cytotoxicity: an evaluation of culture plus cytotoxin assay of Clostridium difficile isolates in the laboratory diagnosis of CDAD. J Hosp Infect 2001; 48:233-7.
17. Delmee M, Van Broeck J, Simon A, Janssens M, Avesani V. Laboratory diagnosis of Clostridium difficile-associated diarrhoea: a plea for culture. J Med Microbiol 2005; 54:187-91.
18. Thonnard J, Carreer F, Avesani V, Delmée M. Toxin A detection on Clostridium difficile colonies from 24-h cultures. Clin Microbiol Infect. 1996; 2:50-4.
19. Sloan LM, Duresko BJ, Gustafson DR, Rosenblatt JE. Comparison of real-time PCR for detection of the tcdC gene with four toxin immunoassays and culture in diagnosis of Clostridium difficile infection. J Clin Microbiol 2008; 46:1996-2001.
20. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45:302-7.
21. Al-Nassir WN, Sethi AK, Nerandzic MM, Bobulsky GS, Jump RL, Donskey CJ. Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin. Clin Infect Dis 2008; 47:56-62.
22. Pelaez T, Alcala L, Alonso R, Rodriguez-Creixems M, Garcia-Lechuz JM, Bouza E. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother 2002; 46:1647-50.
23. Pelaez T, Cercenado E, Alcala L, et al. Metronidazole resistance in Clostridium difficile is heterogeneous. J Clin Microbiol 2008; 46:3028-32.
24. Pillai A, Nelson R. Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev 2008; :CD004611.
25. Munoz P, Bouza E, Cuenca-Estrella M, et al. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis 2005; 40:1625-34.
26. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002; 97:1769-75.
27. McPherson S, Rees CJ, Ellis R, Soo S, Panter SJ. Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea. Dis Colon Rectum 2006; 49:640-5.
28. Wilcox MH. Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea. J Antimicrob Chemother 2004; 53:882-4.
29. Munoz P, Giannella M, Alcala L, et al. Clostridium difficile-associated diarrhea in heart transplant recipients: is hypogammaglobulinemia the answer? J Heart Lung Transplant 2007; 26:907-14.
30. van Dissel JT, de Groot N, Hensgens CM, et al. Bovine antibody-enriched whey to aid in the prevention of a relapse of Clostridium difficile-associated diarrhoea: preclinical and preliminary clinical data. J Med Microbiol 2005; 54:197-205.
31. Numan SC, Veldkamp P, Kuijper EJ, van den Berg RJ, van Dissel JT. Clostridium difficile-associated diarrhoea: bovine anti-Clostridium difficile whey protein to help aid the prevention of relapses. Gut 2007; 56:888-9.
32. Sougioultzis S, Kyne L, Drudy D, et al. Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology 2005; 128:764-70.
33. Aboudola S, Kotloff KL, Kyne L, et al. Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A. Infect Immun 2003; 71:1608-10.
34. Bouza E, Burillo A, Munoz P. Antimicrobial therapy of Clostridium difficile-associated diarrhea. Med Clin North Am 2006; 90:1141-63.